Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Unknown 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Lung Neoplasms 18Breast Neoplasms 11Ovarian Neoplasms 10Uterine Cervical Neoplasms 6Carcinoma, Ovarian Epithelial 6Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Fallopian Tube Neoplasms 5Adenocarcinoma of Lung 5Neoplasms 4Neoplasm Metastasis 4Central Nervous System Neoplasms 4Esophageal Neoplasms 3Small Cell Lung Carcinoma 2Sarcoma 2Retinoblastoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Inflammatory Breast Neoplasms 2Gliosarcoma 2Glioblastoma 2Brain Neoplasms 2Adenocarcinoma, Bronchiolo-Alveolar 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thoracic Neoplasms 1Salivary Gland Neoplasms 1

Interventions

pertuzumab 1Trastuzumab 1Fluorodeoxyglucose F18 1Docetaxel 1Carboplatin 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × HER2-positive Breast Cancer × Carboplatin × Clear all
NCT04419181 2025-10-14

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

University of Rochester

Phase 2 Withdrawn
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡